France Ophthalmic Devices Market Size and Share

France Ophthalmic Devices Market (2025 - 2030)
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
View Global Report

France Ophthalmic Devices Market Analysis by Mordor Intelligence

The France ophthalmic devices market size stands at a current value of USD 2.35 billion, and analysts project it will reach USD 3.68 billion by 2030, reflecting a compound annual growth rate (CAGR) of 7.80% from 2025 to 2030. The steady expansion of the France ophthalmic devices market is underpinned by a surge in premium intraocular lens (IOL) use across public hospitals, wider deployment of optical coherence tomography (OCT) in community practices, and government incentives that reward locally manufactured medical technology. Global brands and French innovators have accelerated product introductions, while artificial-intelligence (AI) software that supports diagnostic imaging is rapidly moving from pilot programs into routine diabetic-retinopathy screening workflows. Technology-driven cost efficiencies are enabling ambulatory surgery centers (ASCs) to capture a higher share of cataract and refractive procedures, adding further momentum to the France ophthalmic devices market. At the same time, reimbursement hurdles for novel hardware and an uneven distribution of ophthalmologists outside large cities temper growth by delaying device adoption in under-served regions, yet the long-term demographic tailwind tied to population ageing keeps the outlook positive.

Key Report Takeaways

  • By device type, vision care products led with 63.0% of the France ophthalmic devices market share in 2024; diagnostic & monitoring devices are projected to advance at a 9.95% CAGR through 2030.
  • By disease indication, cataract accounted for a 39.2% share of the France ophthalmic devices market size in 2024, while Diabetic Retinopathy is expanding at a 9.11% CAGR over 2025-2030.
  • By end-user, hospitals retained 43.6% of spending in the France ophthalmic devices market in 2024; ASCs post the fastest growth at an 8.98% CAGR as the government pushes ambulatory surgery to 80.0% of eligible cases by 2030.

Segment Analysis

By Device Type: Vision Care Dominates While Diagnostics Accelerate

Vision Care products led the France ophthalmic devices market in 2024, with EssilorLuxottica and other suppliers capturing 63.0% of value through a mix of prescription eyewear, contact lenses and myopia-management interventions. The France ophthalmic devices market size for Vision Care reached USD 1.48 billion in 2024 and will expand steadily on the back of Stellest myopia-control lenses, whose real-world data show an average 67.0% slowdown in axial elongation among school-aged users. Innovations in silicone-hydrogel and water-gradient materials are raising wearing comfort, cementing daily-disposable formats as the fastest-rising subcategory. The corporate push into smart spectacles that integrate heads-up displays and biosensors further differentiates product offerings and deepens barriers to entry.

Diagnostic & Monitoring devices represent the most dynamic slice of the France ophthalmic devices market, exhibiting a 9.95% CAGR through 2030 as OCT units, fundus cameras and perimeters embed AI screening modules. Suppliers are pivoting from hardware margins toward subscription models that bundle cloud analytics and upgrade pathways, smoothing revenue visibility. Miniaturization unlocks sales to community optometrists and pharmacies, significantly raising installed bases in areas formerly underserved by hospital imaging. Collaborative purchasing schemes among regional health agencies are also encouraging bulk orders, reducing unit costs and accelerating refresh cycles.

France Ophthalmic Devices Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Get Detailed Market Forecasts at the Most Granular Levels
Download PDF

By Disease Indication: Cataract Leads While Diabetic Retinopathy Accelerates

Cataract therapy maintained the largest share of the France ophthalmic devices market in 2024 at 39.2%, corresponding to USD 921.0 million of the France ophthalmic devices market size. The ambulatory-surgery framework now covers two-thirds of cataract removals, compressing length of stay and raising throughput capacity. Hospitals and ASCs alike are investing in intraoperative aberrometry and femtosecond-laser cataract systems to optimize premium-IOL outcomes, reinforcing the segment’s revenue base. The migration of elderly patients to day-surgery centers accelerates the replacement cycle for phacoemulsification consoles, keeping suppliers’ order pipelines full.

Diabetic-retinopathy solutions deliver the fastest growth, expanding at a 9.11% CAGR. National screening mandates, coupled with AI grading tools, bring previously undiagnosed patients into the treatment funnel, stimulating sales of non-mydriatic fundus cameras and OCT-A modules. Market entrants offering portable, battery-powered imaging units are addressing rural coverage gaps, and their subscription-based software trains continuously on expanding datasets, refining accuracy. The France ophthalmic devices market share for diabetic-retinopathy equipment is set to climb beyond 12% by 2030 as reimbursement shifts to outcome-based bundles that reward early detection.

France Ophthalmic Devices Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Get Detailed Market Forecasts at the Most Granular Levels
Download PDF

By End-user: Hospitals Lead While ASCs Show Rapid Growth

Hospitals generated the largest portion of 2024 expenditure, accounting for 43.6% of the France ophthalmic devices market thanks to superior infrastructure, multidisciplinary teams and leverage in procurement contracts with vendors. A flagship institute that achieved a 97% compliance score in the latest HAS audit continues to pilot cutting-edge devices that later spread to provincial centers. High-volume service lines, including cataract and vitrectomy, underpin attractive economics that incentivize continuous equipment renewal.

ASCs, however, are the star growth performers, with an 8.98% CAGR through 2030 as policymakers target 80% same-day surgery penetration[3]Le Quotidien du Médecin, “Comment augmenter son taux de chirurgie ambulatoire à 80 %,” lequotidiendumedecin.fr. Private-equity backing has fueled a wave of acquisitions, raising capital to install premium IOL-optimized operating microscopes and femtosecond platforms previously confined to tertiary hospitals. The France ophthalmic devices market size for ASCs is expected to surpass USD 1 billion by 2029, reflecting patient preference for streamlined pathways and lower infection risk. Specialty ophthalmic clinics trail in scale yet gain relevance by bundling diagnostics, surgery and postoperative rehab under one roof.

France Ophthalmic Devices Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Get Detailed Market Forecasts at the Most Granular Levels
Download PDF

Geography Analysis

Paris, Lyon and Marseille anchor the highest technology penetration rates in the France ophthalmic devices market, supported by dense ophthalmologist clusters and research-intensive hospitals that catalyze early adoption. The Île-de-France region alone hosts 16 OPHDIAT screening hubs plus EssilorLuxottica’s newly inaugurated excellence laboratory, reinforcing a virtuous cycle of innovation and clinical validation. These urban centers attract fellowship-trained surgeons proficient with premium IOLs and advanced laser systems, delivering treatment volumes that justify rapid device turnover.

Conversely, rural departments in Centre-Val de Loire, Nouvelle-Aquitaine and Occitanie display lower imaging-equipment density, a disparity closely tied to the national shortage of ophthalmologists. Research correlating practitioner density with odds ratios of low vision confirms that regions below the national median for specialists endure higher impairment rates. Teleconsultation cabins, financed through public–private partnerships, are filling part of the gap by hosting slit lamp attachments, fundus cameras and vision-analysis software, forwarding images to urban reading centers for interpretation. Early audits reveal a 32% reduction in missed glaucoma diagnoses in communes adopting the cabin model versus control sites.

Mobile screening units active for 11 years in Burgundy demonstrate another tool for geographic equity, logging over 18,000 patient encounters and reducing referral delays by 40.0%. The France 2030 industrial strategy earmarks USD 450.0 million in grants and low-interest loans to accelerate domestic medical-device manufacturing, stipulating regional deployment benchmarks that favor historically underserved zones. Complementary digital-health initiatives such as the MEDITWIN virtual-twin consortium promise to personalize pre-operative planning, further democratizing access to sophisticated surgical care across all departments.

Competitive Landscape

The France ophthalmic devices market sits at a moderate consolidation level, with the top three groups— EssilorLuxottica SA, Alcon, Inc. and Johnson & Johnson Vision Care—commanding about 66.0% of Vision Care, surgical and diagnostic revenues. EssilorLuxottica leverages vertical integration, a portfolio of heritage and fashion brands, and a strategic pivot into med-tech, evident in its purchase of Heidelberg Engineering and commitment to smart-lens R&D. The company posted USD 30.04 billion in global revenue in 2024, up 4.38% year-on-year, and allocated USD 415.0 million to French R&D and manufacturing expansions.

Alcon focuses on premium IOLs and advanced cataract platforms, reporting high-single-digit revenue growth in implantables for Q2 2024. Rapid uptake of its PanOptix trifocal lens and Vivity non-diffractive EDOF model reflects strong surgeon confidence and direct-to-consumer educational outreach. Johnson & Johnson Vision is consolidating its presence through multifocal contact lenses and the Catalys femtosecond laser, pairing hardware with personalized planning software.

Domestic challengers such as Precilens, Lumibird Medical and Quantel Medical thrive in niche optics, lasers and ultrasound biomicroscopy, often enjoying proximity to France’s defense and aerospace industrial base for precision machining capabilities. Start-ups including OpthAI, which secured CE marking for AI-based fundus-image triage with 100.0% sensitivity, illustrate the shift toward software-as-a-medical-device competitive advantage jfo. Partnerships—such as Zeiss’s collaboration with Boehringer Ingelheim to co-develop retinal-disease analytics—underscore the importance of cross-sector alliances to accelerate pipeline progression and share regulatory risk.

France Ophthalmic Devices Industry Leaders

  1. EssilorLuxottica SA

  2. Alcon Inc.

  3. Carl Zeiss Meditec AG

  4. Johnson & Johnson Vision Care

  5. Topcon Corporation

  6. *Disclaimer: Major Players sorted in no particular order
France Ophthalmic Devices Market.png
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • May 2025: EssilorLuxottica inaugurated a new excellence laboratory in Paris, positioning the site as a hub for smart-lens prototyping and clinical collaboration. The facility underlines national efforts to anchor high-value manufacturing in France.
  • January 2024: The MEDITWIN consortium launched with governmental backing, aiming to build virtual twins that personalize ophthalmic treatment pathways and integrate seamlessly with imaging devices.
  • August 2024: Haute Autorité de Santé issued a favorable reimbursement decision for EYLEA (aflibercept) in neovascular age-related macular degeneration, reinforcing policy support for evidence-backed innovations.
  • May 2024: The Choose France Summit announced health-care investment pledges of EUR 15 billion (USD 16.3 billion), signaling sustained capital inflows to medical technology projects.

Table of Contents for France Ophthalmic Devices Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Adoption of Premium Intraocular Lenses in Post-Cataract Procedures Across Public Hospitals
    • 4.2.2 Rising Penetration of Optical Coherence Tomography in Community Ophthalmology Networks
    • 4.2.3 National Screening Programs for Diabetic Retinopathy Driving Diagnostic Device Uptake
    • 4.2.4 Surge in Refractive Surgery Volumes Fueling Demand for Excimer and Femtosecond Lasers
    • 4.2.5 Government Incentives for Domestic Manufacturing under France 2030 Medical Devices Plan
    • 4.2.6 Integration of AI-based Decision-Support Algorithms into Ophthalmic Imaging Modalities
  • 4.3 Market Restraints
    • 4.3.1 Stringent Haute Autorit de Sant (HAS) Reimbursement Barriers for Novel Devices
    • 4.3.2 Shortage of Trained Ophthalmologists Limiting Device Utilization Outside Major Cities
    • 4.3.3 High Capital Cost of Advanced Surgical Platforms for Small Private Clinics
    • 4.3.4 Post-Covid Supply-Chain Disruptions Impacting Availability of Semiconductor Components
  • 4.4 Regulatory Outlook
  • 4.5 Porter's Five Forces Analysis
    • 4.5.1 Threat of New Entrants
    • 4.5.2 Bargaining Power of Buyers
    • 4.5.3 Bargaining Power of Suppliers
    • 4.5.4 Threat of Substitutes
    • 4.5.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Device Type
    • 5.1.1 Diagnostic & Monitoring Devices
    • 5.1.1.1 OCT Scanners
    • 5.1.1.2 Fundus & Retinal Cameras
    • 5.1.1.3 Autorefractors & Keratometers
    • 5.1.1.4 Corneal Topography Systems
    • 5.1.1.5 Ultrasound Imaging Systems
    • 5.1.1.6 Perimeters & Tonometers
    • 5.1.1.7 Other Diagnostic & Monitoring Devices
    • 5.1.2 Surgical Devices
    • 5.1.2.1 Cataract Surgical Devices
    • 5.1.2.2 Vitreoretinal Surgical Devices
    • 5.1.2.3 Refreactive Surgical Devices
    • 5.1.2.4 Glaucoma Surgical Devices
    • 5.1.2.5 Other Surgical Devices
    • 5.1.3 Vision Care Devices
    • 5.1.3.1 Spectacles Frames & Lenses
    • 5.1.3.2 Contact Lenses
  • 5.2 By Disease Indication
    • 5.2.1 Cataract
    • 5.2.2 Glaucoma
    • 5.2.3 Diabetic Retinopathy
    • 5.2.4 Other Disease Indications
  • 5.3 By End-user
    • 5.3.1 Hospitals
    • 5.3.2 Specialty Ophthalmic Clinics
    • 5.3.3 Ambulatory Surgery Centers (ASCs)
    • 5.3.4 Other End-users

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Alcon Inc.
    • 6.3.2 Bausch Health Companies Inc.
    • 6.3.3 Carl Zeiss Meditec AG
    • 6.3.4 EssilorLuxottica SA
    • 6.3.5 HOYA
    • 6.3.6 Johnson & Johnson Vision Care
    • 6.3.7 Nidek Co., Ltd.
    • 6.3.8 Topcon Corporation
    • 6.3.9 Ziemer Ophthalmic Systems AG
    • 6.3.10 Precilens
    • 6.3.11 Lumibird Medical
    • 6.3.12 Luneau Technology (Visionix)
    • 6.3.13 Heidelberg Engineering GmbH
    • 6.3.14 Optotek Medical
    • 6.3.15 Schwind eye-tech-solutions
    • 6.3.16 Oculus Optikgerte GmbH

7. Market Opportunities & Future Outlook

  • 7.1 White-Space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Research Methodology Framework and Report Scope

Market Definitions and Key Coverage

Our study counts every revenue dollar generated inside France from any medical device whose primary purpose is to test, treat, or correct human vision, including diagnostic imaging systems, surgical hardware, and vision-care products such as contact lenses and spectacles.

Scope exclusions include over-the-counter eye drops, pharmaceutical implants, and service fees that are not sized in this model.

Segmentation Overview

  • By Device Type
    • Diagnostic & Monitoring Devices
      • OCT Scanners
      • Fundus & Retinal Cameras
      • Autorefractors & Keratometers
      • Corneal Topography Systems
      • Ultrasound Imaging Systems
      • Perimeters & Tonometers
      • Other Diagnostic & Monitoring Devices
    • Surgical Devices
      • Cataract Surgical Devices
      • Vitreoretinal Surgical Devices
      • Refreactive Surgical Devices
      • Glaucoma Surgical Devices
      • Other Surgical Devices
    • Vision Care Devices
      • Spectacles Frames & Lenses
      • Contact Lenses
  • By Disease Indication
    • Cataract
    • Glaucoma
    • Diabetic Retinopathy
    • Other Disease Indications
  • By End-user
    • Hospitals
    • Specialty Ophthalmic Clinics
    • Ambulatory Surgery Centers (ASCs)
    • Other End-users

Detailed Research Methodology and Data Validation

Desk Research

We began with public macro and trade data from Sante Publique France, Eurostat health accounts, and UN Comtrade, which outline procedure volumes, import values, and population health risks. Policy notes from Haute Autorite de Sante and the French Ophthalmology Society clarified reimbursement pathways and device adoption rules. Company 10-Ks and investor decks helped us capture selling price shifts, while reputable news archives in Dow Jones Factiva and equipment shipment snapshots in D&B Hoovers supplied early demand signals. The sources listed here illustrate, not exhaust, the references mined by our analysts.

Primary Research

Interviews with hospital purchasing heads, community optometrists, and device distributors across Ile-de-France, Auvergne-Rhone-Alpes, and Provence-Alpes-Cote d'Azur let us validate hospital cap-ex intentions, average selling prices, and product mix shifts that secondary data cannot fully reveal. Inputs from regulatory consultants clarified pending MDR compliance costs.

Market-Sizing & Forecasting

Mordor analysts first built a top-down demand pool using surgical procedure counts, outpatient exam visits, and per-capita spectacle replacement cycles, which are then balanced with selective bottom-up cross-checks such as sampled ASP multiplied by unit shipments reported by key distributors. Critical variables include cataract surgery volume growth, diabetic-retinopathy screening penetration, premium intraocular-lens uptake, euro-to-dollar exchange trends, and public hospital budget ceilings. A multivariate regression links these drivers to historical revenue to forecast 2025-2030, while scenario analysis adjusts for reimbursement reform. Any gaps in distributor rolls are bridged using regional import trends and validated with expert sentiment.

Data Validation & Update Cycle

Outputs run through variance screens against independent procedure tallies and customs data. Senior reviewers question anomalies, and findings loop back to experts where needed before sign-off. We refresh each model annually and trigger interim updates when material events, such as tariff shifts or a blockbuster product recall, occur.

Why Our France Ophthalmic Devices Baseline Stands Firm

Published figures often diverge because firms pick different device lists, price assumptions, and refresh rhythms.

Key gap drivers here include some publishers excluding spectacles, others inflating values by layering service fees, a few converting euros at outdated rates, and several using aggressive premium-lens penetration curves that our hospital checks do not yet confirm.

Benchmark comparison

Market Size Anonymized source Primary gap driver
USD 2.35 B (2024) Mordor Intelligence -
USD 0.65 B (2024) Global Consultancy A Omits vision-care products and applies 3-country average pricing
USD 1.35 B (2024) Industry Portal B Bundles drugs and devices, then splits by fixed 60-40 ratio
USD 1.40 B (2023) Regional Consultancy C Uses 2023 base, rolls forward at flat 5.8 percent without recent procedure rebound

The comparison shows why buyers should rely on Mordor's disciplined scope selection, mixed-method model, and yearly refresh, which together give a balanced, transparent baseline that decision makers in France's eye-care ecosystem can trust.

Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current value of the France ophthalmic devices market?

The France ophthalmic devices market size is USD 2.53 billion in 2025.

How fast is the market expected to grow?

Analysts forecast a 7.80% CAGR from 2025 to 2030, driving value to USD 3.68 billion by the end of the period.

Which device category holds the largest share?

Vision Care dominates with 63.0% of the France ophthalmic devices market share, led by EssilorLuxottica’s extensive eyewear and contact-lens portfolio.

Why are ambulatory surgery centers growing so quickly?

Government policy aims to push eligible procedures to outpatient settings, and ASCs offer lower costs and faster turnaround, resulting in an 8.98% CAGR.

What is the biggest growth opportunity by disease indication?

Diabetic-retinopathy devices are expanding at a 9.11% CAGR due to national screening programs and AI-driven diagnostic platforms.

How do reimbursement rules affect device adoption?

Stringent HAS evaluations can delay market entry for novel devices, reducing near-term uptake but incentivizing strong clinical-evidence generation for long-term success.

Page last updated on:

France Ophthalmic Devices Market Report Snapshots